Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

Phase 1 Completed 10 enrolled Alaunos Therapeutics

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Single arm, open label, Phase I, dose-escalation study of indibulin in combination with erlotinib in subjects with advanced histologically confirmed, solid tumors for which no standard therapy exists and for whom treatment with erlotinib is considered medically acceptable.

Timeline

Start: 2008-01
Primary completion: 2008-12
Completion: 2009-12

Publications

Kapoor S, Srivastava S, Panda D. Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy. Sci Rep. 2018 Aug 17;8(1):12363. doi: 10.1038/s41598-018-30376-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	indibulin	Small molecule	200 mg	—
Subject	indibulin	Small molecule	600 mg	—
Background	Erlotinib	Small molecule	150 mg	—

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications